Your browser doesn't support javascript.
loading
Research progress of EGFRvIII targeted immunotherapy in the treatment of glioblastoma / 药学学报
Acta Pharmaceutica Sinica ; (12): 2662-2670, 2022.
Article Dans Chinois | WPRIM | ID: wpr-941525
ABSTRACT
Glioblastoma (GBM) is the most common primary brain tumor, which is prone to recurrence and metastasis with poor prognosis. In recent years, immunotherapy has prolonged the survival of patients with GBM, providing a new option for the treatment of GBM. Target selection is very important for immunotherapy. Epidermal growth factor receptor variant III (EGFRvIII) is highly expressed on the surface of GBM cells in some patients, and EGFRvIII was not expressed in normal tissues. EGFRvIII are pivotal for the occurrence and progression of GBM, various targeted therapy including immunotherapy is promising to improve the efficacy of GBM. Currently, there are various approaches to target EGFRvIII, including humanized monoclonal antibodies, adoptive cell therapies and therapeutic vaccines. In this review, we focus on the preclinical and clinical findings of targeting EGFRvIII for GBM.

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Type d'étude: Étude pronostique langue: Chinois Texte intégral: Acta Pharmaceutica Sinica Année: 2022 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Type d'étude: Étude pronostique langue: Chinois Texte intégral: Acta Pharmaceutica Sinica Année: 2022 Type: Article